ARGX (ARGX) Stock Price & Analysis
ARGX (ARGX) fell 0.69% to USD 918.22 as of July 25, 2026 at 03:08 UTC, according to Nexqual real-time market data.
ARGX last closed at USD 924.6; the session ranged USD 910.19–935.88 on volume of 311,578 shares. Market capitalization is $57.10B, with a 52-week range of USD 587.37–953.58 (NMS). Source: Nexqual, July 25, 2026 at 03:08 UTC.
Key Statistics (as of July 25, 2026 at 03:08 UTC)
| Price | USD 918.22 |
|---|---|
| Change | ▼ 0.69% (down) |
| Previous Close | USD 924.6 |
| Open | USD 934.55 |
| Day Range | USD 910.19 – 935.88 |
| 52-Week Range | USD 587.37 – 953.58 |
| Volume | 311,578 shares |
| Market Cap | $57.10B |
| Exchange | NMS |
Technical Analysis (ARGX)
Nexqual's technical model rates ARGX "BUY" based on 5 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 03:08 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.24 (neutral) |
| vs SMA50 | Above (USD 864.28) |
| MACD | 4.52 (positive) |
Analyst Ratings (ARGX)
Wall Street analysts rate ARGX "Buy" based on 23 analysts, with a mean price target of USD 1,079.39 (range USD 770–1,291), per Nexqual as of July 25, 2026 at 03:08 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 1,079.39 |
| High Target | USD 1,291 |
| Low Target | USD 770 |
| Buy / Hold / Sell | 22 / 2 / 1 |
Earnings (ARGX)
| Next Earnings Date | 2026-10-22 |
|---|---|
| EPS Estimate | USD 7.43 |
| Revenue Estimate | $1.63B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 7.32 vs est 6.19 ▲ beat |
| 2026-03-31 | USD 5.52 vs est 4.92 ▲ beat |
| 2025-12-31 | USD 8.02 vs est 6.11 ▲ beat |
| 2025-09-30 | USD 5.18 vs est 4.16 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financials & Fundamentals (ARGX)
| Total Revenue | $5.32B |
|---|---|
| Revenue Growth (YoY) | +59.30% |
| Gross Margin | +59.07% |
| Operating Margin | +31.99% |
| Profit Margin | +32.27% |
| ROE | +23.64% |
| Debt / Equity | 0.56 |
| Current Ratio | 5.12 |
| Total Cash | $5.18B |
| Total Debt | $47.00M |
| Free Cash Flow | $761.77M |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Financial Health Score (ARGX)
Nexqual rates ARGX's overall financial health "Strong" across five dimensions, as of July 25, 2026 at 03:08 UTC.
| Growth | Strong — Revenue +89% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 59%, operating 32% |
| Balance Sheet | Strong — $5.18B cash vs $47M debt, net cash position |
| Cash Flow | Strong — FCF $762M, 18% margin |
| Efficiency | Strong — ROE 24%, ROA 11.6% |
Ownership (ARGX)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +47.33% |
| Shares Outstanding | 62.19M |
| Float | 1.56B |
| Short % of Float | +2.33% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Leadership (ARGX)
ARGX is led by Karen Massey (age 46), CEO & Executive Director, per Nexqual as of July 25, 2026 at 03:08 UTC.
| CEO & Executive Director | Karen Massey (age 46) |
|---|---|
| Co-Founder & Non-Independent Non-Executive Chairman of the Board | Timothy Van Hauwermeiren EMBA, M.Sc. (age 53) |
| Chief Financial Officer | Karl Gubitz (age 55) |
| Chief Scientific Officer | Peter Ulrichts (age 45) |
| Vice President of Corporate Development & Strategy | Arjen Lemmen M.Sc. (age 40) |
Major Backers & Investors (ARGX)
Notable institutional backers of ARGX include FMR, LLC, Price (T.Rowe) Associates Inc, Janus Henderson Group PLC, according to Nexqual as of July 25, 2026 at 03:08 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 7.98% |
| Price (T.Rowe) Associates Inc | 5.39% |
| Janus Henderson Group PLC | 4.06% |
| Capital Group | 3.61% |
| Artisan Partners Limited Partnership | 2.35% |
| Fidelity | 1.73% |
| Wellington Management | 1.63% |
| Avoro Capital Advisors LLC | 1.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 2.56% |
Source: Nexqual, July 25, 2026 at 03:08 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ASND | Ascendis Pharma A/S | USD 253.86 | ▲ 0.77% |
| KRYS | Krystal Biotech, Inc. | USD 335.19 | ▼ 0.48% |
| GMAB | Genmab A/S | USD 28.87 | ▲ 0.07% |
| ALNY | Alnylam Pharmaceuticals, Inc. | USD 271.77 | ▲ 1.79% |
| LKFT | Lakefront Biotherapeutics | USD 27.84 | ▼ 3.27% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:08 UTC. This page is informational and not investment advice.